My father was diagnosed with Multiple Myeloma (MM) in 2003 and was in remission until 2019. Since his relapse, he has been undergoing continuous treatment. Initially, in 2019, he was administered Velcade (2mg) and Dexamethasone (20mg) every fortnight. He then transitioned to Darzalex (1200mg) alongside Dexamethasone (16mg) for 25 cycles from February 2021 to May 2022. Since May 2022, his treatment plan includes Velcade (2mg) every two weeks along with weekly Dexamethasone (12mg). Despite these treatments, I am becoming increasingly worried about the progression of his disease. His Serum Free Kappa/Lambda ratio has been on a steady rise, currently at 2.65. This indicates a probable increase in monoclonal protein, further evidenced by a persistent faint M band in the gamma region. Additionally, his S. Free Kappa Light chains are at 28.43 mg/l, while his S. Free Lambda Light chains are at 10.7 mg/l. While I understand that treatment decisions are personalized and can be complicated, I can't help but feel that his current treatment may not be adequately managing his progressing disease. My primary focus is to ensure that he receives the most effective and optimal treatment possible. Considering the increasing Kappa/Lambda ratio, rising light chain levels, and the continuous presence of the M band, I would highly value your input on his current treatment plan's appropriateness. Are there other treatment options or modifications that we should consider? I am reaching out to you for your expert advice to ensure I am advocating for the best possible care for my father.